Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: More than 4years of experience

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 5, 2014, Pages 456-465

  Angelo, Maria Genalin ^a   Zima, Julia ^a   Tavares Da Silva, Fernanda ^a   Baril, Laurence ^a   Arellano, Felix ^a  

^a GSK   (Belgium)

Author keywords

Adverse drug reactions; AS04; Human papillomavirus vaccine; Pharmacoepidemiology; Post licensure surveillance; Potential immune mediated diseases; Pregnancy

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; IMMUNOLOGICAL ADJUVANT;

ABDOMINAL PAIN; ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADOLESCENT; ADULT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHENIA; AUTOIMMUNE HEPATITIS; BELL PALSY; CHILD; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG LEGISLATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENCEPHALITIS; FAINTNESS; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNIZATION; INCIDENCE; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LIVER DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MUSCULOSKELETAL DISEASE; MYALGIA; MYASTHENIA GRAVIS; MYELITIS; NARCOLEPSY; NAUSEA; OPTIC NEURITIS; PALLOR; PAPILLOMAVIRUS INFECTION; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; POPULATION; PREGNANCY; PREGNANCY OUTCOME; PRESYNCOPE; PREVENTIVE HEALTH SERVICE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN DISEASE; UNITED KINGDOM; VASCULAR DISEASE; VOMITING; PAPILLOMAVIRUS INFECTIONS; POSTMARKETING SURVEILLANCE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINATION;

EID: 84898040343     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3593     Document Type: Review

References (39)

1. Macartney KK, Chiu C, Georgousakis M, Brotherton JML. Safety of human papillomavirus vaccines: a review. Drug Saf 2013; 36: 393-412.
2. Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization. 2012. http://www.meddramsso.com/ (accessed 21 November 2012).
3. Report of CIOMS Working Group IV. Benefit-risk balance for marketed drugs: evaluating safety signals. 1998. http://www.cioms.ch/publications/g4-benefit-risk.pdf (accessed 21 November 2012).
4. Verstraeten T, Descamps D, David M-P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26: 6630-6638.
5. Cervarix Summary of Product Characteristics. 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac058001d124 (accessed 21 November 2012).
6. Angelo M-G, David M-P, Zima J, et al. Pooled analysis of large and long-term safety data from the human papillomavirus (HPV)-16/18-AS04-adjuvanted vaccine clinical trial programme (in press).
7. Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group. Eur J Clin Pharmacol 1997; 52: 423-427.
8. Wu H, Fung M, Hornbuckle K, Muniz E. Impact of geographic and cross-cultural differences on spontaneous adverse events reporting. Drug Inf J 1999; 33: 921-931.
9. Medicines and Healthcare products Regulatory Agency (MHRA). Public assessment report. Cervarix (HPV vaccine): update on UK safety experience at the end of 4years use in the HPV routine immunisation programme. December 2012. http://www.mhra.gov.uk/PrintPreview/DefaultSplashPP/CON023340?ResultCount=10&DynamicListQuery=&DynamicListSortBy=xCreationDate&DynamicListSortOrder=Desc&DynamicListTitle=&PageNumber=1&Title=Human%20papillomavirus%20(HPV)%20vaccine (accessed 17 January 2013).
10. Gasparini R, Bonanni P, Levi M, et al. Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study. Hum Vaccin 2011; 7(Suppl): 136-146.
11. van't Klooster T, Kemmeren J, Vermeer-de-Bondt P, et al. Adverse events following vaccination against human papillomavirus: results of the 2010 campaign in the Netherlands. 2011. http://www.rivm.nl/en/Library/Scientific/Reports/2011/december/Adverse_events_following_vaccination_against_human_papillomavirus_Results_of_the_2010_campaign_in_the_Netherlands?sp=cml2bXE9ZmFsc2U7c2VhcmNoYmFzZT01OTAzMDtyaXZtcT1mYWxzZTs=&pagenr=5904 (accessed 10 September 2012).
12. Bonhoeffer J, Heininger U, Kohl K, et al. Standardized case definitions of adverse events following immunization (AEFI). Vaccine 2004; 22: 547-550.
13. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
14. Tavares da Silva F, De Keyser F, Lambert P-H, et al. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine 2013; 31(14): 1870-1876.
15. Rowlands S, Hooper R, Hughes R, Burney P. The epidemiology and treatment of Bell's palsy in the UK. Eur J Neurol 2002; 9: 63-67.
16. Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 2006; 166: 1301-1304.
17. Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29: 599-612.
18. Siegrist C-A, Lewis EM, Eskola J, Evans SJW, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 2007; 26: 979-984.
19. Savettieri G, Salemi G, Rocca WA, et al. Incidence and lifetime prevalence of Bell's palsy in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Acta Neurol Scand 1996; 94: 71-75.
20. European Medicines Agency (Committee for Medicinal Products for Human Use). Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data. London, EMEA, 2005.
21. Birth defects and genetic diseases branch 6-digit code for reportable congenital anomalies. http://www.cdc.gov/ncbddd/birthdefects/documents/macdpcode0807.pdf (accessed 05 Sept 2013).
22. Rasmussen SA, Olney RS, Holmes LB, et al. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res Part A Clin Mol Teratol 2003; 67: 193-201.
23. Bánhidy F, Lowry RB, Czeizel AE. Risk and benefit of drug use during pregnancy. Int J Med Sci 2005; 2: 100-106.
24. Polifka JE, Friedman JM. Medical genetics: 1. Clinical teratology in the age of genomics. CMAJ 2002; 167: 265-273.
25. Dolk H, Loane M, Garne E. The prevalence of congenital anomalies in Europe. Adv Exp Med Biol 2010; 686: 349-364.
26. Correa A, Cragan JD, Kucik JE, et al. Reporting birth defects surveillance data 1968-2003. Birth Defects Res Part A Clin Mol Teratol 2007; 79: 65-186.
27. Saraiya M, Berg CJ, Shulman H, Green CA, Atrash HK. Estimates of the annual number of clinically recognized pregnancies in the United States, 1981-1991. Am J Epidemiol 1999; 149: 1025-1029.
28. Seamark C. Design or accident? The natural history of teenage pregnancy. J R Soc Med 2001; 94: 282-285.
29. Ventura SJ, Abma JC, Mosher WD, Henshaw SK. Estimated pregnancy rates by outcome for the United States, 1990-2004. Natl Vital Stat Rep 2008; 56: 1-25, 28.
30. Devine S, West S, Andrews E, et al. The identification of pregnancies within the general practice research database. Pharmacoepidemiol Drug Saf 2010; 19: 45-50.
31. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. 2010. http://www.eurosurveillance.org/viewarticle.aspx?ArticleId=19730 (accessed 7 September 2012).
32. Medicines and Healthcare products Regulatory Agency (MHRA). MHRA Public Assessment Report. Cervarix (HPV vaccine): update on UK safety covering the first two years of the HPV immunisation programme. October 2010. http://www.mhra.gov.uk/PrintPreview/DefaultSplashPP/CON023340?ResultCount=10&DynamicListQuery=&DynamicListSortBy=xCreationDate&DynamicListSortOrder=Desc&DynamicListTitle=&PageNumber=1&Title=Human%20papillomavirus%20(HPV)%20vaccine (accessed 7 September 2012).
33. Medicines and Healthcare products Regulatory Agency (MHRA). YellowCard. Helping to make medicines safer. 2012. http://yellowcard.mhra.gov.uk/ (accessed 17 January 2012).
34. Medicines and Healthcare products Regulatory Agency (MHRA). Human papillomavirus (HPV) vaccine. http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-G-L/HumanpapillomavirusHPVvaccine/index.htm (accessed 17 January 2013).
35. Wise L, Parkinson J, Raine J, Breckenridge A. New approaches to drug safety: a pharmacovigilance tool kit. Nat Rev Drug Discov 2009; 8: 779-782.
36. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20: C40-C44.
37. Global Advisory Committee on Vaccine Safety. Wkly Epidemiol Rec 2013; 88: 301-312.
38. Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25: 5771-5792.
39. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.